RANDOMIZED CONTROLLED TRIAL OF EFFICACY OF MOSAPRIDE ON RECOVERY OF INTESTINAL MOTILITY AFTER ELECTIVE COLORECTAL CANCER SURGERY

Tharin Thampongsa

UEG Week Copenhagen 2023 | Poster

Colorectal

October 16, 2023

A randomized controlled trial of 44 colorectal surgery patients found that mosapride 15 mg three times daily starting postoperative day 1 significantly shortened time to first bowel movement, passage of flatus, and hospital stay compared to placebo.

KEY POINTS

- Mosapride group had significantly shorter time to first bowel movement (40 vs 70 hours, P=0.003) and first passage of flatus (26 vs 50 hours, P=0.004) compared to control group
- Hospital stay was significantly shorter in the mosapride group (7 vs 10 days, P=0.004)
- Time to soft diet (90 vs 132 hours, P=0.004) and time to defecate (80 vs 120 hours, P<0.001) were both significantly shorter with mosapride
- No significant adverse effects were observed in the mosapride group
- This triple-blind randomized controlled trial included patients undergoing open and laparoscopic colorectal cancer surgery at Ramathibodi Hospital between July 2021 and August 2022

VIEW THIS CONTENT ON GUTFLIX

https://gutflix.eu/search/d/48092fb2-743b-11ee-84df-0242ac140004

AI-generated summary

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.